Claims for Patent: 10,527,604
✉ Email this page to a colleague
Summary for Patent: 10,527,604
Title: | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
Abstract: | The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising paclitaxel coated with albumin and a non-nanoparticle portion comprising albumin and paclitaxel. |
Inventor(s): | Peykov; Viktor (San Diego, CA), Foss; Willard (San Diego, CA), Pierce; Daniel W. (Belmont, CA), Desai; Neil P. (Pacific Palisades, CA) |
Assignee: | ABRAXIS BIOSCIENCE, LLC (Summit, NJ) |
Application Number: | 15/062,050 |
Patent Claims: | 1. A method of assessing suitability of a pharmaceutical composition for medical use in a human individual, wherein the pharmaceutical composition comprises (a)
nanoparticles comprising paclitaxel coated with a coating comprising albumin and (b) a non-nanoparticle portion comprising albumin and paclitaxel, the method comprising: separating the nanoparticles from the non-nanoparticle portion; measuring a weight
percentage of albumin in the form of albumin polymers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles; and assessing the suitability of the pharmaceutical composition for medical use in
a human individual, wherein a weight percentage of albumin in the form of albumin polymers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles being about 15% to about 40% is indicative of
suitability of the pharmaceutical composition for medical use.
2. A method of assessing suitability of a pharmaceutical composition for medical use in a human individual, wherein the pharmaceutical composition comprises (a) nanoparticles comprising paclitaxel coated with a coating comprising albumin and (b) a non-nanoparticle portion comprising albumin and paclitaxel, the method comprising: separating the nanoparticles from the non-nanoparticle portion; measuring a weight percentage of albumin in the form of albumin monomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles; and assessing the suitability of the pharmaceutical composition for medical use in a human individual, wherein a weight percentage of albumin in the form of albumin monomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles being about 40% to about 60% is indicative of suitability of the pharmaceutical composition for medical use. 3. The method of claim 1, wherein the method further comprises measuring a weight percentage of albumin in the form of albumin monomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles, wherein a weight percentage of albumin in the form of albumin monomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles being about 40% to about 60% is indicative of suitability of the pharmaceutical composition for medical use. 4. The method of claim 2, wherein the method further comprises measuring a weight percentage of the albumin in the coating of the separated nanoparticles compared to the total weight of the separated nanoparticles, wherein a weight percentage of the albumin in the coating of the separated nanoparticles compared to the total weight of the separated nanoparticles being about 15% to about 30% is indicative of suitability of the pharmaceutical composition for medical use. 5. The method of claim 2, further comprising determining the weight ratio of the albumin in the coating of the separated nanoparticles to paclitaxel in the nanoparticles, wherein an albumin to paclitaxel ratio of about 1:2 to about 1:6 in the nanoparticles is indicative of suitability of the pharmaceutical composition for medical use. 6. The method of claim 2, further comprising determining the thickness of the coating of the nanoparticles by cryogenic transmission electron microscopy, wherein a thickness of about 5-7 nm as determined by cryogenic transmission electron microscopy is indicative of suitability of the pharmaceutical composition for medical use. 7. The method of claim 2, further comprising determining the solubility of the nanoparticles in a 5% human albumin solution by dynamic light scattering, wherein a solubility of about 50 .mu.g/ml to about 100 .mu.g/ml in the 5% human albumin solution as determined by dynamic light scattering is indicative of suitability of the pharmaceutical composition for medical use. 8. The method of claim 2, further comprising determining the paclitaxel crystallinity of the paclitaxel in the nanoparticles of the pharmaceutical composition, wherein a non-crystalline state of the paclitaxel is indicative of suitability of the pharmaceutical composition for medical use, and wherein the paclitaxel crystallinity is determined by X-ray diffraction or polarized light microscopy. 9. The method of claim 2, further comprising determining the paclitaxel recovery following a 0.2 micron filtration of the pharmaceutical composition, wherein a paclitaxel recovery of at least about 80% is indicative of suitability of the pharmaceutical composition for medical use. 10. The method of claim 7, wherein the determination of nanoparticle solubility is carried out after storage. 11. The method of claim 2, further comprising measuring a weight percentage of albumin in the form of albumin dimers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles, wherein a weight percentage of albumin in the form of albumin dimers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles as determined by size-exclusion chromatography being about 15% to about 30% is indicative of suitability of the pharmaceutical composition for medical use. 12. The method of claim 2, further comprising measuring a weight percentage of albumin in the form of albumin oligomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles, wherein a weight percentage of albumin in the form of albumin oligomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles as determined by size-exclusion chromatography being about 7% to about 15% is indicative of suitability of the pharmaceutical composition for medical use. 13. The method of claim 2, further comprising measuring a weight percentage of albumin in the form of albumin monomers, albumin dimers, albumin oligomers, or albumin polymers in the pharmaceutical composition among the total albumin in the pharmaceutical composition. 14. The method of claim 13, wherein the weight percentage of albumin in the form of albumin monomers, albumin dimers, albumin oligomers, or albumin polymers in the pharmaceutical composition among the total albumin in the pharmaceutical composition is measured by size-exclusion chromatography. 15. The method of claim 2, further comprising determining the particle size of the nanoparticles. 16. The method of claim 15, wherein the particle size of the nanoparticles is determined by dynamic light scattering. 17. The method of claim 2, further comprising determining the polydispersity index of the nanoparticles in the pharmaceutical composition. 18. The method of claim 2, further comprising determining the span of size distribution ((Dv.sub.90-Dv.sub.10)/Dv.sub.50) of the nanoparticles in the pharmaceutical composition wherein Dv.sub.90 is the particle diameter where 90% of the volume of all nanoparticles is contained in nanoparticles with smaller diameters; wherein Dv.sub.10 is the particle diameter where 10% of the volume of all nanoparticles is contained in nanoparticles with smaller diameters; and wherein Dv.sub.50 is the volume-weighted median particle diameter. 19. The method of claim 2, further comprising determining the surface potential of the nanoparticles. 20. The method of claim 2, further comprising measuring a weight percentage of the paclitaxel in the separated nanoparticles among the total paclitaxel in the pharmaceutical composition. 21. The method of claim 20, wherein the percentage of the paclitaxel in the nanoparticles is determined by reversed-phase high performance liquid chromatography. 22. The method of claim 2, further comprising measuring a weight percentage of the albumin that is in the non-nanoparticle portion among the total albumin in the pharmaceutical composition. 23. The method of claim 22, wherein the percentage of the albumin is determined by size-exclusion chromatography. 24. The method of claim 2, wherein the weight ratio of the total albumin to the total paclitaxel in the pharmaceutical composition is about 3:1 to about 7.9:1 or about 10:1 to about 17:1. 25. The method of claim 2, wherein the albumin is human albumin. 26. The method of claim 2, wherein the average particle size of the nanoparticles is less than about 200 nm as determined by dynamic light scattering. 27. A method of validating a commercial batch of a pharmaceutical composition for medical use in a human individual, wherein the pharmaceutical composition comprises (a) nanoparticles comprising paclitaxel coated with a coating comprising albumin and (b) a non-nanoparticle portion comprising albumin and paclitaxel, and wherein the method comprises 1) obtaining a sample from the commercial batch, and 2) assessing suitability of the sample for medical use according to claim 2. 28. A commercial batch of a pharmaceutical composition for medical use in a human individual, wherein the pharmaceutical composition comprises (a) nanoparticles comprising paclitaxel coated with a coating comprising albumin and (b) a non-nanoparticle portion comprising albumin and paclitaxel, and wherein the commercial batch is validated by assessment of suitability for medical use according to claim 2. 29. The method of claim 1, further comprising measuring a weight percentage of albumin in the form of albumin monomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles, wherein a weight percentage of albumin in the form of albumin monomers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles being less than about 51% is indicative of suitability of the pharmaceutical composition for medical use. 30. The method of claim 2, further comprising measuring a weight percentage of albumin in the form of albumin monomers, albumin oligomers, and albumin polymers in the coating of the separated nanoparticles among the total albumin in the coating of the separated nanoparticles, wherein a ratio the sum of the weight percentage of albumin in the form of albumin polymers in the coating of the separated nanoparticles and the weight percentage of albumin in the form of albumin oligomers in the coating of the separated nanoparticles compared to the weight percentage of albumin in the form of albumin monomers in the coating of the separated nanoparticles being more than about 65% is indicative of the suitability of the pharmaceutical composition for medical use. 31. A method of releasing a commercial batch of a pharmaceutical composition comprising (a) nanoparticles comprising paclitaxel coated with a coating comprising albumin and (b) a non-nanoparticle portion comprising albumin and paclitaxel, the method comprising: assessing the suitability of the pharmaceutical composition for medical use in a human individual using a sample of the commercial batch, wherein the suitability of the pharmaceutical composition is assessed according to the method of claim 2; and releasing the commercial batch if the pharmaceutical composition is suitable for medical use. 32. A method of processing a sample of a pharmaceutical composition to validate the sample as suitable for medical use in a human individual, the pharmaceutical composition comprising (a) nanoparticles comprising paclitaxel coated with a coating comprising albumin and (b) a non-nanoparticle portion comprising albumin and paclitaxel, the method comprising: obtaining the sample from a commercial batch; and assessing the suitability of the pharmaceutical composition for medical use in a human individual using a sample of the commercial batch, wherein the suitability of the pharmaceutical composition is assessed according to the method of claim 2. |
Details for Patent 10,527,604
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Grifols Therapeutics Llc | ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | albumin (human) | For Injection | 101138 | 10/21/1942 | ⤷ Try a Trial | 2035-03-05 |
Baxalta Us Inc. | BUMINATE, FLEXBUMIN | albumin (human) | Injection | 101452 | 03/03/1954 | ⤷ Try a Trial | 2035-03-05 |
Csl Behring Ag | ALBURX | albumin (human) | Injection | 102366 | 07/23/1976 | ⤷ Try a Trial | 2035-03-05 |
Grifols Biologicals Llc | ALBUTEIN | albumin (human) | Injection | 102478 | 08/15/1978 | ⤷ Try a Trial | 2035-03-05 |
Instituto Grifols, S.a. | HUMAN ALBUMIN GRIFOLS | albumin (human) | Injection | 103352 | 02/17/1995 | ⤷ Try a Trial | 2035-03-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.